Salem Radio Network News Tuesday, December 6, 2022

Health

Factbox-Eisai-Biogen Alzheimer’s drug success follows many failures

(Reuters) – Eisai Co Ltd and Biogen Inc reported late-stage data from their Alzheimer’s disease drug lecanemab that showed it significantly slowed cognitive decline, a big win for patients after a long string of failures to find an effective treatment for the memory-robbing disease.

Options are limited as Biogen’s Aduhelm, the first new Alzheimer’s treatment in 20 years, has not been widely used due to severe limits on its coverage by Medicare and insurers. The following is a list of high profile Alzheimer’s disease trial failures:

Company Drug name Trial outcome Mechanism of

action

Roche crenezumab Although small A monoclonal

numerical antibody

differences targeting toxic

favored protein plaque

crenezumab, the in the brain

results were not known as beta

statistically amyloid to slow

significant and disease

potentially due progression.

to chance.

Biogen gosuranemab Drug failed to An antibody

meet any directed

efficacy goals against “tau”

in trial. proteins

believed to

play a role in

Alzheimer’s.

Roche and AC semorinemab The drug failed Targeted “tau”

Immune to slow proteins.

cognitive and

functional

decline in

trial.

Roche and Eli gantenerumab Combination Designed to

Lilly , failed to arrest neutralize

solanezumab cognitive beta-amyloid

decline in those plaques.

afflicted by

gene mutations.

Neurotrope bryostatin-1 Drug did not Designed to

Inc, now show any induce growth

called significant of synapses in

Synaptogenix difference in the brain and

Inc patients after prevent cell

13 weeks in a death.

mid-stage trial.

Merck & Co verubecestat Did A beta

not work in secretase

late-stage cleaving enzyme

trials in (BACE)

patients with inhibitor,

both very early which aims to

Alzheimer’s and prevent amyloid

those with mild- buildup.

to-moderate

Alzheimer’s.

Eli Lilly and solanezumab In a late-stage Targets

Co study, patients beta-amyloid,

treated with the Alzheimer’s

solanezumab did protein that

not experience a forms sticky

significantly plaques in the

greater slowing brain.

in cognitive

decline vs

placebo.

AstraZeneca, lanabecestat Companies Beta secretase

Eli Lilly discontinued cleaving enzyme

late-stage (BACE)

trials of the inhibitor,

drug after which aims to

independent prevent amyloid

committee buildup.

concluded they

were unlikely to

succeed.

Johnson & atabecestat BACE inhibitor

Johnson Stopped

development in

mid-stage trials

after

participants

showed serious

elevations of

liver enzymes.

The company

concluded the

risk outweighed

potential

benefits.

Novartis, CNP520 Companies BACE inhibitor

Amgen, Banner discontinued two

Alzheimer’s mid-to-late-stag

Institute e studies after

identifying

worsening of

some measures of

cognitive

function in

treatment

groups.

Pfizer Inc, bapineuzumab The drugmakers Beta-amyloid

Johnson & called off targeting

Johnson additional work monoclonal

after the drug antibody.

failed to help

patients with

mild-to-moderate

Alzheimer’s in

its second round

of clinical

trials.

Biogen and elenbecestat The companies BACE inhibitor

Eisai Co scrapped two

late-stage

studies in

patients with

early

Alzheimer’s,

after

independent

committee

recommended

discontinuation

due to an

unfavorable

risk-benefit

ratio.

(Reporting by Bhanvi Satija, Raghav Mahobe and Manas Mishra in Bengaluru; Editing by Bill Berkrot)

Previous
Next

Editorial Cartoons

View More »

Steve Breen
Thu, Dec 1, 2022

X CLOSE